17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WTB-Raf-expressing uveal melanoma cell lines

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 6, 2008, Pages 2348-2356

  Babchia, Narjes ^a,b,c   Calipel, Armelle ^a,b,c,d   Mouriaux, Frédéric ^a,b,c,d   Faussat, Anne Marie ^a   Mascarelli, Frédéric ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; B RAF KINASE; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NITROBLUE TETRAZOLIUM; PROTEIN KINASE B; SMALL INTERFERING RNA; STEM CELL FACTOR; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; BRAF PROTEIN, HUMAN; CYCLIN D; CYCLINE; MACROCYCLIC LACTAM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL TRANSFORMATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA MELANOMA; WESTERN BLOTTING; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; MELANOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UVEA TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RNA, SMALL INTERFERING; UVEAL NEOPLASMS;

EID: 47249096580     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1305     Document Type: Article

References (37)

1. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of b-raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem. 2003;278:42409-42418. (Pubitemid 37310512)
2. Cohen Y, Goldenberg-Cohen N, Parrella P, et al. Lack of B-raf mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:2876-2878. (Pubitemid 36759747)
3. Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of B-raf and N-ras mutations in uveal melanoma. Cancer Res. 2003;63:5761-5766.
4. Gear H, Williams H, Kemp EG, Roberts F. B-raf mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45:2484-2488.
5. Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ, Zwarthoff EC. No mutations in human uveal melanoma: the role of ultraviolet light revisited. Br J Cancer. 1991;64:411-413.
6. Rimoldi D, Salvi S, Lienard D, et al. Lack of B-raf mutations in uveal melanoma. Cancer Res. 2003;63:5712-5715. (Pubitemid 37187465)
7. Soparker CN, O'Brien JM, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci. 1993;34:2203-2209. (Pubitemid 23191246)
8. Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. B-raf mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14:449-452. (Pubitemid 40221134)
9. Karasarides M, Chiloeches A, Hayward R, et al. B-raf is a therapeutic target in melanoma. Oncogene. 2004;23:6292-6298. (Pubitemid 39215299)
10. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-raf pathway in human uveal melanoma cells. J Biol Chem. 2006;281:9238-9250. (Pubitemid 43864639)
11. Weber A, Hengge UR, Urbanik D, et al. Absence of mutations of the B-raf gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest. 2003;83:1771-1776. (Pubitemid 38018540)
12. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of Br-af or ras. Br J Cancer. 2005;92:2032-2038. (Pubitemid 40897426)
13. Lefevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem. 2004;279:31769-31779. (Pubitemid 39037849)
14. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel raf kinase inhibitor. Endocr Relat Cancer. 2001;8:219-225. (Pubitemid 32947644)
15. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant v599eb-raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65:2412-2421. (Pubitemid 40490153)
16. Goetz CA, O'Neil JJ, Farrar MA. Membrane localization, oligomerization, and phosphorylation are required for optimal raf activation. J Biol Chem. 2003;278:51184-51189. (Pubitemid 38020355)
17. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 2004;10:283-290. (Pubitemid 38725896)
18. Maloney A, Workman P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2:3-24. (Pubitemid 34462457)
19. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004;562:11-15. (Pubitemid 38388440)
20. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs. 2005;10:137-149. (Pubitemid 40293075)
21. Missotten GS, Journee-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ. Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:3059-3065. (Pubitemid 36759773)
22. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein Hsp90-pp60v-Src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994;91:8324-8328. (Pubitemid 24273656)
23. Grbovic OM, Basso AD, Sawai A, et al. V600e B-raf requires the Hsp90 chaperone for stability and is degraded in response to hsp90 inhibitors. Proc Natl Acad Sci U S A. 2006;103:57-62. (Pubitemid 43076104)
24. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-raf is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2005;65:10686-10691.
25. Casagrande F, Bacqueville D, Pillaire MJ, et al. G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY294002 is correlated to up-regulation of p27Kip1 and inhibition of g1 Cdks in choroidal melanoma cells. FEBS Lett. 1998;422:385-390. (Pubitemid 28075501)
26. Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH. P50(cdc37) acting in concert with Hsp90 is required for raf-1 function. Mol Cell Biol. 1999;19:1661-1672. (Pubitemid 29098225)
27. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of raf-1 involves the proteasome. Biochem Biophys Res Commun. 1997;239:655-659. (Pubitemid 27504156)
28. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol. 2005;56:126-137. (Pubitemid 40884268)
29. Lefevre G, Calipel A, Mouriaux F, Hecquet C, Malecaze F, Mascarelli F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene. 2003;22:8813-8822. (Pubitemid 38021497)
30. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated kit protein in human mast cells. Blood. 2004;103:1078-1084. (Pubitemid 38129574)
31. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A. 2000;97:10832-10837.
32. Pearl LH. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr Opin Genet Dev. 2005;15:55-61. (Pubitemid 40127632)
33. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56:115-125. (Pubitemid 40884267)
34. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. Bcr- Abl point mutants isolated from patients with imatinib mesylateresistant chronic myeloid leukemia remain sensitive to inhibitors of the Bcr-Abl chaperone heat shock protein 90. Blood. 2002;100:3041-3044.
35. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs. 2004;15:377-387. (Pubitemid 38526763)
36. Isaacs JS. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? Expert Opin Investig Drugs. 2005;14:569-589. (Pubitemid 40895187)
37. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706-1712. (Pubitemid 41079810)